RSS

Novartis

A brief round up of some of the latest developments in the industry, including a review into medical marijuana and a potential win for Trump in drug pricing… more

Opinion

The European Commission (EC) has approved Novartis’ Aimovig (erenumab) for the prevention of migraine in adults experiencing four or more migraines per month. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

In this case study, a prediction model is used in conjunction with an examination of a tablet profile to resolve sticking issues. more

Opinion

The US FDA has accepted Novartis’ supplemental new drug application (sNDA) and granted priority review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of SAA more

News

The group general counsel of Swiss pharma company, Novartis, has stepped down from his role, taking personal responsibility for what he has described as the ‘erroneous’ agreement made with Essential Consultants, which is owned by Michael Cohen more

News

A treatment for relapsing multiple sclerosis (Gilenya — fingolimod) has been approved for use in children and adolescents aged 10 years and older by the US Food and Drug Administration (FDA). more

News

Two drugs, to be administered together for the treatment of ATC that cannot be surgically removed or has spread and has a type of abnormal gene, BRAF V600E, Tafinlar (dabrafenib) and Mekinist (trametinib), have been approved by the FDA more

News

Swiss-based healthcare company, Novartis, has revealed that the US Food and Drug Administration (FDA) has approved its CAR-T therapy, Kymriah, for its second distinct indication. more

News

Swiss-based company, Novartis, has launched a digital research platform created with Apple ResearchKit — FocalView app — which it hopes will modernise ophthalmic clinical trials making them more accessible and flexible. more

Technology

Healthcare solutions provider, Novartis, is set to gain further ground in the area of gene therapy through its agreement to acquire AveXis — US-based clinical stage gene therapy company — for $8.7 billion. more

News

According to data and analytics company, GlobalData, pharmaceutical sales within the age-related macular degeneration (AMD) markets will soar to $11.5 billion by the year 2026. more

Analysis

Healthcare solutions provider, Novartis, has entered into an agreement with GlaxoSmithKline to divest its 36.5% stake in its consumer healthcare joint venture for $13 billion. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

A collaboration between healthcare solutions provider, Novartis, and Pear Therapeutics has been announced that aims to develop digital therapeutics for patients with schizophrenia and multiple sclerosis (MS). more

Technology

Novartis has formed an alliance with the Bill & Melinda Gates Foundation to further develop its drug candidate, KDU731, for the treatment of cryptosporidiosis — a cause of infectious diarrhoea in children. more

News

Novartis plans to transition the use of its treatment for certain chronic lymphocytic leukaemia (CLL), Arzerra (ofatumumab), from commercial availability to limited availability via compassionate use programmes in all markets except the US. more

News

Two recently published clinical studies have demonstrated a new approach using antibodies to target specific chemicals in the brain may help significantly reduce the incidence and severity of migraines. more

News

Two life-extending drugs will now be available to breast cancer patients on the NHS after price negotiations lead the National Institute for Health and Care Excellence (NICE) to approve them. more

News

Novartis has announced a collaboration with biotech company, Homology Medicines, to adapt and refine the technology for the treatment of a blood disorder and certain eye diseases. more

News